Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platformBuilt on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicabilitySAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions ...